Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib for Progressive HCC Post-ICI (CAPIO)
NCT07151326Phase 2Not yet recruiting
- Sponsor
- National Health Research Institutes
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by National Health Research Institutes. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07151326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151326.